Industry7 min read
CagriSema vs Tirzepatide: REIMAGINE 4 Diabetes Data
Novo's amylin/GLP-1 combo matched tirzepatide on weight but missed on blood sugar in the 68-week REIMAGINE 4 head-to-head. What it means for buyers.
Peptide News & Analysis
FDA actions, trial readouts, vendor coverage and pricing reports — curated for peptide buyers and clinicians.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Latest News
Industry7 min read
Pfizer Kills Oral GLP-1 Peptide: What's Left in Pipeline
Pfizer axed its ex-Metsera oral GLP-1 peptide and a phase 2 GIPR antagonist. What survived the cut, and what it changes for research-peptide sourcing.
Industry7 min read
What Doctors Think About Peptides: New Survey Data
48% of physicians say patients disclosed peptide use last year — and 84% got their information from influencers, not doctors. The full survey data.
Regulatory8 min read
Compounded GLP-1s: FDA Docket Closed, 3,901 Comments
The FDA's plan to bar 503B bulk compounding of semaglutide, tirzepatide and liraglutide drew 3,901 comments before the July 30 cutoff. What survives.
Regulatory7 min read
FDA Maps Generic Path for Semaglutide, Tirzepatide
The FDA published 17 revised generic-peptide guidances and pulled its 2021 synthetic-peptide rule. What it changes for GLP-1 pricing and access.
Industry7 min read
Novo Sues Lilly Over GLP-1 Ads: The Dose Mismatch
Novo asked a court to halt Lilly's GLP-1 ads for pitting max-dose tirzepatide against outdated semaglutide doses. What the trial data actually shows.
Regulatory6 min read
The $2.2B Race to Sell You Prescription BPC-157
Leerink pegs compounded peptides at a $2.2B telehealth market and Hims jumped 10% on the FDA vote. What the prescription route means for price and timing.
Industry8 min read
Are Peptides Legal in the US? What the FDA Vote Means
Most peptides aren't FDA-approved drugs — which isn't the same as illegal. The plain-English answer, and what the FDA's July vote did and didn't change.
Industry4 min read
Buy Peptides With Crypto: Vendors & Discounts
Card networks keep dropping peptide sellers, so crypto is now the default. Which vendors take Bitcoin, who adds a crypto discount, and how it works.
Trials5 min read
Retatrutide TRIUMPH-2/3: 22.6% Loss in Diabetes & CVD
Lilly's retatrutide met endpoints in two Phase 3 trials — up to 22.6% weight loss in obesity with diabetes and heart disease. What buyers should know.
Industry6 min read
FDA Panel Backs 6 Peptides for Compounding, Rejects DSIP
FDA advisers backed 6 of 7 peptides for compounding — Semax and Epitalon included — and rejected DSIP, all over staff objections. Every vote tally.
Trials7 min read
Boehringer's BI 3034701: New Triple-Agonist in Phase 2
Boehringer's BI 3034701, a GLP-1/GIP/NPY2 triple agonist, entered Phase 2 for obesity. How it differs from retatrutide and what buyers can get now.
Trials5 min read
Bioglutide (NA-931) Phase 2: 13.8% Oral Weight Loss
The Phase 2 trial reported oral quadruple agonist NA-931 hit 13.8% weight loss with no muscle loss. How it stacks up to retatrutide.
Industry5 min read
Peptides for Long COVID: What the Trials Show
BPC-157, MOTS-c and microdosed GLP-1s are marketed for Long COVID while semaglutide and tirzepatide trials run. What's studied, what isn't.
Vendors3 min read
Mile High Compounds Review: Bioregulators, Sprays & Codes
Bioregulators, Cerebrolysin, LL-37 and ready-made nootropic sprays, plus per-batch testing and a 4.7 Trustpilot score. Where Mile High fits, and 10% off.
Regulatory5 min read
FDA's Next Peptide Panel: GHK-Cu, Melanotan, Dihexa
The FDA scheduled a second peptide panel by early 2027: GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF are next. What buyers should know.
Trials6 min read
KAI-7535: New Oral GLP-1 Pill Hits 11% Weight Loss
Kailera's KAI-7535 oral GLP-1 pill hit up to 11% weight loss in Phase 3 — but it's years from shelves. Here's what you can access today.
Industry5 min read
GLP-1 Use Hits Record 11% as US Obesity Rate Falls
GLP-1 use hit a record 11% of US adults as obesity fell to 36.4% — Gallup's first decline. What the surge means for access, cost, and cheaper routes.